Detail akcie Bavarian Nordic online

Business Summary: Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Bavarian Nordic A/S revenues increased from DKR3.15B to DKR7.06B. Net income totaled DKR1.48B vs. loss of DKR347.4M. Revenues reflect Sale of goods - MVA-BN smallpox vaccine sale segment increase from DKR1.73B to DKR5.03B, Sale of goods - Rabipur/RabAvert segment increase of 32% to DKR1.16B, United States segment increase from DKR841.5M to DKR2.58B, Canada segment increase from DKR197.3M to DKR1.56B.